奈达铂腹腔灌注联合希罗达治疗晚期胃癌腹腔积液

Intraperitoneal perfusion of nedaplatin combined with xeloda in the treatment of ascites in patients with advanced gastric carcinoma

目的观察腹腔灌注奈达铂联合希罗达治疗晚期胃癌的疗效及安全性。方法共入组经病理证实的晚期胃癌56例,治疗方案为奈达铂80 mg/m2,腹腔灌注;希罗达2 000 mg/m2,口服,每天2次,1～14 d,休息1周,21 d为1个周期,至少应用2个周期后进行评价。结果可评价疗效的50例中,完全缓解(CR)1例(2%),部分缓解(PR)34例(68%),疾病稳定(SD)12例(24%),疾病进展(PD)3例(6%),客观有效率(ORR)为70%,中位无进展生存期为5.9个月,中位生存期14.9个月,主要不良反应为骨髓抑制、恶心、呕吐及手足综合征。结论腹腔灌注奈达铂联合希罗达治疗晚期胃癌疗效较好,毒性可耐受。

Objective To investigate the efficacy and safety of intraperitoneal perfusion of nedaplatin combined with xeloda in the treatment of ascites in patients with advanced gastric carcinoma.Methods A total of 56 patients with advanced gastric carcinoma which were diagnosed by histological examination of biopsy specimens were recruited.Nedaplatin were perfused into peritoneal cavity at a dose of 80 mg/m2;xeloda was taken orally at a dose of 2000 mg/m2,twice daily for 1-14 consecutive days with one week rest,21 days for a cycle,the evaluation of efficacy and safety were performed on all patients after 2 cycles at least.Results Among the 50 patients with evaluated efficacy,1 case achieved complete remission（CR） accounting for 2%;34 cases had partial remission（PR） accounting for 68%;12 cases were with stable disease（SD） accounting for 24%;3 cases were with progressive disease（PD） accounting for 6%.The objective response rate（ORR） was 70%.The median progression-free survival was 5.9 months and the median survival was 14.9 months.The major adverse reactions were myelosuppressio,nausea,vomiting and hand-foot syndrome.Conclusion Intraperitoneal perfusion of nedaplatin combined with xeloda in treating ascites in patients with advanced gastric carcinoma is safe and effective.Drug-related adverse events are mild and well-tolerated.